About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01173497

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Update: This study is no longer recruiting patients.

Study identifier: NCT01173497
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Iniparib (Sanofi Aventis)

Eligibility:

Triple-negative breast cancer with brain lesion on radiographic imaging

Type of study:

Phase II study

Treatment:

Participants receive a combination of iniparib and irinotecan

Study sites:

Update: This study is no longer recruiting patients.

Page updated 06/13/13    


Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org